Allogene Therapeutics Inc (NASDAQ:ALLO)’s traded shares stood at 2.19 million during the last session, with the company’s beta value hitting 1.01. At the close of trading, the stock’s price was $1.95, to imply a decrease of -4.41% or -$0.09 in intraday trading. The ALLO share’s 52-week high remains $5.78, putting it -196.41% down since that peak but still an impressive 32.31% since price per share fell to its 52-week low of $1.32.
Analysts have given a consensus recommendation of Buy for Allogene Therapeutics Inc (ALLO), translating to a mean rating of 1.38. Of 6 analyst(s) looking at the stock, 0 analyst(s) give ALLO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.32.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
After registering a -4.41% downside in the last session, Allogene Therapeutics Inc (ALLO) has traded red over the past five days. The 5-day price performance for the stock is -13.53%, and 1.04% over 30 days. With these gigs, the year-to-date price performance is -8.45%.
The extremes give us $7 and $55 for target low and target high price respectively. As such, ALLO has been trading -2720.51% off suggested target high and -258.97% from its likely low.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
The rating firms project that company’s revenue will shrink -68.42% compared to the previous financial year.
Revenue forecast for the current quarter as set by 16 analysts is 10.5k. Meanwhile, for the current quarter, a total of 12 analyst(s) estimate revenue growth to 4.17k.Earnings reports from the last fiscal year show that sales brought in 21k and 22k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -50.00% before dropping -81.05% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 22.18% for the past 5-year period. While 2025 is set for a 38.14% return in earnings, projections for the next 5 years are at 12.85% annually.
ALLO Dividends
Allogene Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is TPG GP A, LLC with 18.72 million shares, or about 9.8493% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $43.61 million.
We also have Smallcap World Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Allogene Therapeutics Inc (ALLO) shares. Going by data provided on Sep 30, 2024 , Smallcap World Fund holds roughly 6.9 shares. This is just over 3.29% of the total shares, with a market valuation of $13.45 million. Data from the same date shows that the other fund manager holds a little less at 4.34, or 2.07% of the shares, all valued at about 8.46 million.
